Catalyst Pharmaceuticals, Inc. (CPRX) Stock Analysis
Breakout setup · Catalyst-Driven edge
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $27.70, but acceptable to hold if already in. Reasons: Concentration risk — Product: FIRDAPSE and AGAMREE small target patient populations; Concentration risk — Supplier: Santhera (AGAMREE active ingredients) and Eisai (FYCOMPA supplies).
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome... Read more
Hold if already holding. Not a fresh buy at $27.70, but acceptable to hold if already in. Reasons: Concentration risk — Product: FIRDAPSE and AGAMREE small target patient populations; Concentration risk — Supplier: Santhera (AGAMREE active ingredients) and Eisai (FYCOMPA supplies). Chart setup: Golden cross, above all MAs, RSI 66, MACD bullish. Maintain position. Not compelling to add more. Score 6.8/10, moderate confidence.
Passes 4/6 gates (positive momentum, clean insider activity, no SEC red flags, semi cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductFIRDAPSE and AGAMREE small target patient populations10-K Item 1A: 'Because the target patient populations for FIRDAPSE® and AGAMREE® are small, we must achieve significant market share and obtain relatively high per-patient prices for our products to achieve meaningful gross margins.'
- HIGHSupplierSanthera (AGAMREE active ingredients) and Eisai (FYCOMPA supplies)10-K Item 1A: 'we currently purchase AGAMREE® active ingredients from Santhera while working to complete our own manufacturer arrangements for the product and also purchase FYCOMPA® supplies from Eisai through at least the end of 2029'
- MEDIUMSupplierlicensing partner for AGAMREE and FYCOMPA10-K Item 1A: 'We are dependent on our licensing partner for supplies of AGAMREE® and FYCOMPA®.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
10 dimensions · all in-band
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $27.70, but acceptable to hold if already in. Reasons: Concentration risk — Product: FIRDAPSE and AGAMREE small target patient populations; Concentration risk — Supplier: Santhera (AGAMREE active ingredients) and Eisai (FYCOMPA supplies). Chart setup: Golden cross, above all MAs, RSI 66, MACD bullish. Maintain position. Not compelling to add more. Target $29.58 (+6.8%), stop $25.76 (−7.5%), A.R:R 0.6:1. Score 6.8/10, moderate confidence.
Take-profit target: $29.58 (+6.8% upside). Target $29.58 (+6.8%), stop $25.76 (−7.5%), A.R:R 0.6:1. Stop-loss: $25.76.
Concentration risk — Product: FIRDAPSE and AGAMREE small target patient populations; Concentration risk — Supplier: Santhera (AGAMREE active ingredients) and Eisai (FYCOMPA supplies); Thin upside margin: 6.8%.
Catalyst Pharmaceuticals, Inc. trades at a P/E of 16.8 (forward 9.1). TrendMatrix value score: 7.8/10. Verdict: Hold.
14 analysts cover CPRX with a consensus score of 4.4/5. Average price target: $34.
What does Catalyst Pharmaceuticals, Inc. do?Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing...
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizure; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.